Mogrify
Mogrify is a preclinical UK biopharmaceutical company that develops proprietary computational platforms (MOGRIFY, epiMOGRIFY) to predict transcription-factor combinations for direct cellular reprogramming, and applies them to in vivo therapies for hearing loss, vision loss, and Type 1 diabetes via partnerships, notably with Astellas.
- Company typePrivate
- Founded2016
- HeadquartersCambridge, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Mogrify does
Mogrify Limited is a UK-based, privately held preclinical biopharmaceutical company developing a novel class of in vivo reprogramming therapies for degenerative diseases with high unmet clinical need, initially targeting indications in otology, ophthalmology, diabetes, and immuno-oncology. The company operates from a single site at the Bio-Innovation Centre, Cambridge Science Park, with a headcount in the 11-50 range (and a stated 60+ as of 2020).
Mogrify's core asset is a proprietary suite of computational platform technologies designed to systematically identify the transcriptomic and epigenetic switches that drive direct cellular reprogramming. The MOGRIFY platform uses transcriptomic and gene-regulatory-network data to predict optimal combinations of transcription factors for converting any cell type into any other, via enhanced forward programming or transdifferentiation that bypasses the pluripotent stem-cell state. The epiMOGRIFY platform complements this with an epigenetic (H3K4me3 histone modification) layer that predicts culture conditions to maintain cell identity and support reprogramming in chemically defined media, enabling cGMP-grade manufacturing use cases. The MOGRIFY V2 algorithm, exclusively licensed from the MRC Laboratory of Molecular Biology, adds next-generation bulk and single-cell RNA sequencing data to improve prediction accuracy. The technology is protected by a foundational patent (covering 30+ conversions, originated from RIKEN, University of Bristol and Monash University) plus pending conversion-specific patents.
Mogrify commercializes its platform through three revenue streams, none of which involve product sales: (i) licensing of MOGRIFY and epiMOGRIFY to biopharma partners for therapeutic and non-therapeutic applications; (ii) co-development partnerships with pharmaceutical companies, exemplified by a 2022 collaboration with Astellas Pharma on in vivo regenerative medicine for sensorineural hearing loss; and (iii) internal pipeline development of in vivo reprogramming therapies, with named programs MOG1 (retinal degeneration), MOG2 (sensorineural hearing loss, with Astellas) and MOG3 (Type 1 diabetes). The company is venture-backed, having raised approximately $49M+ across a $3.7M seed (Feb 2019) and a $46M Series A executed across three closes (Oct 2019, May 2021, Oct 2023), with corporate strategic investor Astellas co-leading the most recent extension.
Mogrify firmographics
Firmographics- Name
- Mogrify
- Legal name
- Mogrify Limited
- Website
- https://mogrify.co.uk
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Mogrify is a preclinical UK biopharmaceutical company that develops proprietary computational platforms (MOGRIFY, epiMOGRIFY) to predict transcription-factor combinations for direct cellular reprogramming, and applies them to in vivo therapies for hearing loss, vision loss, and Type 1 diabetes via partnerships, notably with Astellas.
- Ownership category
- akta.pro rank
Mogrify industry classification
Industry- Product category
- Regenerative Medicine Platform
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)
Keywords
Where Mogrify is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United Kingdom
- HQ region
- Europe
Offices1 record
Markets served
Mogrify business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Revenue model
- Platform Licensing: Licensing of MOGRIFY® and epiMOGRIFY® platform technologies to biopharma companies for therapeutic and non-therapeutic applications
- Co-development Partnerships: Joint development agreements with pharmaceutical companies to develop in vivo reprogramming therapies for specific disease areas
- Therapeutic Development: Internal development of in vivo reprogramming therapies for ophthalmology, otology, diabetes, and other degenerative diseases with high unmet clinical need
Go-to-market motion2 records
Distribution channels2 records
Marketing channels7 records
Mogrify product offering
Product offeringCore offering
Mogrify develops and commercializes proprietary bioinformatic platform technologies (MOGRIFY® and epiMOGRIFY®) that systematically identify transcriptomic and epigenetic switches required for direct cellular reprogramming. The company applies these platforms to build a pipeline of in vivo reprogramming therapies targeting degenerative diseases in otology, ophthalmology (retinal degeneration), and diabetes (Type 1), and licenses the underlying platforms to biopharmaceutical partners for therapeutic and non-therapeutic applications.
Product overview
Mogrify has developed a proprietary suite of platform technologies centered around two core products: MOGRIFY (a direct cellular reprogramming platform) and epiMOGRIFY (an epigenetically-driven cell identity platform). These platforms work together to systematically identify transcription factors and culture conditions required to produce any target cell type from any source cell type. The company applies these platforms to develop a pipeline of in vivo reprogramming therapies, including programs for retinal degeneration (MOG1), sensorineural hearing loss (MOG2), and Type I diabetes (MOG3). The technology enables both enhanced stem-cell forward programming and direct transdifferentiation between mature cell types.
Differentiator
Problem solved
Functional benefit
Products and services
- MOGRIFY Platform A direct cellular reprogramming platform that systematically identifies optimal combinations of transcription factors required to convert any cell type into any other cell type. It uses transcriptomic data and gene regulatory network analysis to predict conversion factors, enabling enhanced forward programming or direct transdifferentiation without going through a pluripotent stem cell state. Licensed to biopharmaceutical companies for therapeutic and non-therapeutic applications.
- epiMOGRIFY Platform A cell identity platform that identifies optimal combinations of transcription factors and growth factors required to maintain cell identity and epigenetically support reprogramming in chemically defined media. The platform leverages epigenetic data including H3K4me3 histone modifications to predict culture conditions for cGMP manufacture and scalable off-the-shelf therapies.
- MOG1 (Retinal Degeneration Program) An in vivo reprogramming therapy pipeline program targeting retinal degeneration, aiming to restore vision loss through direct conversion of cells in the eye.
- MOG2 (Sensorineural Hearing Loss Program) An in vivo reprogramming therapy pipeline program targeting sensorineural hearing loss, developed in collaboration with Astellas, aiming to generate new cochlear hair cells through direct cellular conversion.
- MOG3 (Type 1 Diabetes Program) An in vivo reprogramming therapy pipeline program targeting Type 1 diabetes, aiming to restore pancreatic beta cell function through direct conversion approaches.
Quantifiable outcome
- Validated 13 cell conversions in vitro as documented in foundational patent
Companies that use Mogrify
Customer profileSegments2 records
Ideal customer profiles1 record
Mogrify technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature3 records
Mogrify partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core and major.
- Astellas Pharma Inc.coreCollaborative research agreement on in vivo regenerative medicine approaches to address sensorineural hearing loss. Astellas Gene Therapies covering research costs and contributing AAV-based genetic medicine expertise. Mogrify exploiting its bioinformatic platform to characterize potential therapeutic factors for cochlear hair cell regeneration.
- MRC Laboratory of Molecular BiologycoreExclusive license of enhanced MOGRIFY V2 technology incorporating next-generation RNA sequencing data. With support from LifeArc, bringing latest algorithm in-house for improved transcription factor predictions.
- RIKENmajorAssignment of rights in foundational patent underpinning direct cell conversion technology (MOGRIFY V1). Part of multi-national research collaboration.
- University of BristolmajorAssignment of rights in foundational MOGRIFY patent. University of Bristol Enterprise Fund is also an investor in the company.
- Monash UniversitymajorAssignment of rights in foundational MOGRIFY patent. Co-development partner for epiMOGRIFY platform. Professor Jose Polo serves as co-founder from Monash.
- Duke-NUS Medical SchoolmajorCo-development partner for epiMOGRIFY platform. Associate Professor Enrico Pettreto and Assistant Professor Owen Rackham (co-founder) involved in platform development.
Scale indicators5 records
Recent moves7 records
Expansion highlights5 records
Mogrify competitors and assessment
Company assessmentDirect peers
- Sana Biotechnology: Engineered cell therapy platform pursuing in vivo cell engineering approaches for regenerative medicine and oncology. Directly comparable as a platform biotech pursing in vivo + ex vivo cell engineering.
- Fate Therapeutics: Pioneer in iPSC-derived cell therapies using engineered multiplexed cell products. Comparable regenerative medicine platform with multiple pharma partnerships and clinical-stage programs.
- Century Therapeutics: Develops iPSC-derived allogeneic cell therapies for cancer and autoimmune diseases. Comparable as a next-generation engineered cell therapy platform competing for pharma partnerships in the regenerative medicine space.
- bit.bio: Cambridge UK-based cell reprogramming company developing iPSC-derived cell therapies using a precision cellular reprogramming platform. Direct competitor in direct cellular conversion technology targeting similar regenerative medicine applications.
Emerging players
- Capsida Biotherapeutics: Engineered AAV gene therapy platform company pursuing CNS indications. Comparable as a next-generation platform biotech targeting genetically defined and degenerative diseases with a programmable delivery + cargo approach.
- Vor BioPharma: Cell therapy + genome editing platform developing engineered hematopoietic stem cell therapies for oncology and regenerative medicine. Comparable in pursuing programmable cell-based regenerative medicine approaches.
- Aspect Biosystems: Canada-based bioprinting and cell therapy platform developing tissue therapeutics for metabolic and ophthalmologic diseases. Comparable in targeting regenerative medicine with cell-based therapeutics for similar indications.
- Cellino Biotech: Cambridge-based AI-driven iPSC platform for regenerative medicine. Early-stage peer with overlapping cell reprogramming technology and Cambridge ecosystem roots.
Broad incumbents
- BlueRock Therapeutics: Bayer-owned cell therapy platform focused on iPSC-derived regenerative therapies for neurology, cardiology, and ophthalmology. Established incumbent with significant capital and competing programs in Mogrify's target indications.
Others
- RIKEN Center for Life Science Technologies: Japanese research institute whose FANTOM 5 transcriptomic consortium and foundational direct cell conversion patent rights are licensed to Mogrify. Strategic technology licensor and co-developer rather than direct competitor.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Mogrify social profiles
Digital presenceMogrify financial estimates
Financial estimateRevenue estimate
Valuation estimate
Mogrify leadership team
Management profileNumber of profiles
Profiles12 records
Mogrify funding detail
Funding detailFunding overview
Funding rounds6 records
Investors8 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Mogrify M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Mogrify
What does Mogrify do?
Mogrify develops and commercializes proprietary bioinformatic platform technologies (MOGRIFY® and epiMOGRIFY®) that systematically identify transcriptomic and epigenetic switches required for direct cellular reprogramming. The company applies these platforms to build a pipeline of in vivo reprogramming therapies targeting degenerative diseases in otology, ophthalmology (retinal degeneration), and diabetes (Type 1), and licenses the underlying platforms to biopharmaceutical partners for therapeutic and non-therapeutic applications.
Is Mogrify a public or private company?
Mogrify is a private company. It is classified as venture growth investor backed and is currently operating.
When was Mogrify founded?
Mogrify was founded in 2016. It employs 11 to 50 people.
Where is Mogrify based?
Mogrify is headquartered in Cambridge, United Kingdom, in the Europe region.
How does Mogrify make money?
Three revenue lines are on record. Platform Licensing is the primary driver. The others are co-development Partnerships and therapeutic Development.
Who are Mogrify's main competitors?
Direct peers on record are Sana Biotechnology, Fate Therapeutics, Century Therapeutics and bit.bio. Emerging players are Capsida Biotherapeutics, Vor BioPharma, Aspect Biosystems and Cellino Biotech. BlueRock Therapeutics is listed as a broad incumbent. RIKEN Center for Life Science Technologies is listed as an others.
Does Mogrify have an API?
No public API is recorded for Mogrify.
What industry is Mogrify in?
Mogrify's product category is Regenerative Medicine Platform. Its primary akta.pro industry code is HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 541714 and its SIC code is 2836.